Mimoun et al1 were first to describe a peculiar yellowish pattern in patients with age-related macular degeneration (AMD) as reticular pseudodrusen (RPD) in 1990. Since that time, improved identification and clinical descriptions of RPD and their dynamic nature have become possible with the development of newer imaging modalities including infrared and spectral domain optical coherence tomography (SD OCT) imaging. By most investigators, RPD are considered to be associated with or at least have some developmental relationship to subretinal drusenoid deposits, which have been identified histopathologically as residing internal to the retinal pigment epithelium.

A retrospective study found that a commonly prescribed drug for Parkinson’s, L-DOPA, may delay or prevent AMD.

This study adds to the growing body of literature that suggests natamycin may be more effective for treating fungal keratitis than voriconazole.

Ophthotech announced that Genentech will join Novartis and split rights to pegpleranib (Fovista) for the treatment of wet AMD.

Allergan announced that its biodegradable sustained-release bimatoprost implant is comparable to daily topical bimatoprost.

The U.S. FDA has granted orphan drug designation to AGTC’s gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene.